Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1- infected patients with and without AIDS dementia complex

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 1, 1999, Pages 39-43

  Aweeka, Francesca ^a   Jayewardene, Anura ^a   Staprans, Silvija ^b   Bellibas, S Eralp ^b   Kearney, Brian ^a   Lizak, Patricia ^a   Novakovic Agopian, Tatjana ^b   Price, Richard W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cerebrospinal fluid; Nelfinavir; Pharmacokinetics

Indexed keywords

ABACAVIR; DELAVIRDINE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LUMBAR PUNCTURE; MALE; PRIORITY JOURNAL;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032948171     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199901010-00006     Document Type: Article

References (18)

1. Price RW, Brew B. The AIDS dementia complex. J Infect Dis 1988;158:179-83.
2. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-90.
3. Flexner C. HIV-protease inhibitors. N Engl J Med 1988;338:1281-92.
4. Emini EA. Resistance to anti-human immunodeficiency virus therapeutic agents. Adv Exper Med Biol 1995;390:187-95.
5. + T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
6. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. AIDS 1997;11:F95-9.
7. Price RW. Management of AIDS dementia complex. HIV-1 infection of the nervous system. AIDS 1995;9(Suppl A):S221-30.
8. Gendelman HE, Lipton SA, Epstein L, Swindells S. The neurology of AIDS. New York: Chapman & Hall, 1988.
9. Richman D. HIV therapeutics [viewpoints]. Science 1996;272: 1886-7.
10. Price RW, Staprans S. Measuring "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? [editorial, comment]. Ann Neurol 1997;42:675-8.
11. Perry CM, Benfield P. Nelfinavir. Drugs 1997;54:81-7.
12. Agouron Pharmaceuticals, Inc. Package insert for nelfinavir mesylate. San Diego, CA: Agouron Pharmaceuticals, 1997).
13. Manufacturer information, Agouron Pharmaceuticals, Inc. Personal communication, February, 1997.
14. Agouron Pharmaceuticals, Inc. Investigators' brochure. San Diego, CA: Agouron Pharmaceuticals, Inc., 1997.
15. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs. Cell 1994;77: 491-502.
16. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of the HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
17. Stahle L, Martin C, Svensson J-O, Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1 infected patients [letter]. Lancet 1997;350:1823.
18. Brinkman K, Kroon F, Hugen PWH, Burger DM. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients. AIDS 1998;12:537.